Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

@article{Leal2011DoseescalatingAP,
  title={Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study},
  author={Ticiana B. Leal and Scot C. Remick and Chris H M Takimoto and Ramesh K. Ramanathan and Angela M. Davies and Merrill J. Egorin and Anne Hamilton and Patricia Lorusso and Stephen I. Shibata and H. P. Lenz and J. G. M. van Mier and John Sarantopoulos and Sridhar Mani and John Joseph Wright and S Percy Ivy and Rachel B Neuwirth and Lisa L. von Moltke and Karthik Venkatakrishnan and Daniel L. Mulkerin},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2011},
  volume={68},
  pages={1439-1447}
}
To determine the toxicities, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of bortezomib in patients with renal impairment and to develop dosing guidelines for such a patient population. Sixty-two adult cancer patients received intravenous bortezomib at 0.7–1.5 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Patients were stratified by 24-h creatinine clearance (CrCl) normalized to body surface area (BSA) 1.73 m2 into five cohorts: normal renal function (≥60 ml/min/1.73 m2); mild… CONTINUE READING
16 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Pharmacokinetic (PK) and pharmacodynamics (PD) study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma

  • AK Stewart, D Sullivan, S Lonial
  • (MM). Blood 108:1008a
  • 2006
Highly Influential
4 Excerpts

A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients

  • MA Dimopoulos, P Richardson, R Schlag
  • Blood 112:1727a
  • 2008
2 Excerpts

Bortezomib-doxorubicin-dexamethasone (BDD) for reversal of acute light chain induced renal failure (ARF) in multiple myeloma (MM). Results from a phase II study

  • H Ludwig, Z Adam, R Hajek
  • Blood 112:Abstr
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…